Taiwanese vaccine maker Adimmune Corp (國光生技) yesterday said it has received approval from the Chinese government for it to start phase three clinical trials of its flu vaccine in China, enabling it to enter the market next year.
The company plans to launch the vaccine immediately after receiving Chinese approval in the first half of next year, company vice president Simon Kao (高聖凱) said.
The company expects to sell less than 1 million vials of vaccine in China next year, but the volume should increase to between 3 million and 5 million vials in 2016, accounting for 10 percent of the market, Kao said.
There are currently 10 companies making flu vaccines in 0.5cc vials, and nine making 0.25cc vials. Adimmune is capable of making vaccines in both sizes, Kao said.
Flu vaccine in China is priced between 10 yuan and 60 yuan (US$1.65 and US$9.85) per vial, while the average price of Adimmune’s will be between 50 yuan and 60 yuan, Kao said.
The company sells 1.5 million vials of flu vaccine in Taiwan at between NT$100 to NT$150 each, it said, adding that domestic sales of the vaccine would account for 40 percent of its revenue this year.
Thanks to the Cross-strait Cooperation Agreement on Medicine and Public Health Affairs (兩岸醫藥衛生合作協議), the company spent only three years to get the green light to start the phase three trials, shorter than five to six years for other companies, Kao said.
“We will be the first company to launch a medical product in China without building a plant there,” chairman Steve Chan (詹啟賢) said.
Meanwhile, Chan said Adimmune’s vaccine for H7N9 avian influenza will complete phase one clinical trails by January and phase two clinical trials by June.
From January through last month, the company posted revenue of NT$273.8 million (US$9.32 million), up 18.23 percent from NT$231.57 million a year ago, as sales to its partner, Dutch-based Crucell, rose to 370g from 200g last year, chief financial officer Vic Chang (張哲瑋) said.
Sales to Crucell, which account for 60 percent of the company’s revenue this year, are expected to increase next year as the company started to provide about 75g to 100g adjuvants for curing hepatitis A, which are twice as expensive as its flu vaccine, Chang said.
Adimmune is likely to remain in the red this year, he said.
The company reported losses of NT$309.25 million in the first half of the year, compared with losses of NT$284.74 million a year ago.
Adimmune‘s shares rose 6.07 percent to NT$47.15 yesterday.
TECH TITAN: Pandemic-era demand for semiconductors turbocharged the nation’s GDP per capita to surpass South Korea’s, but it still remains half that of Singapore Taiwan is set to surpass South Korea this year in terms of wealth for the first time in more than two decades, marking a shift in Asia’s economic ranks made possible by the ascent of Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). According to the latest forecasts released on Thursday by the central bank, Taiwan’s GDP is expected to expand 4.55 percent this year, a further upward revision from the 4.45 percent estimate made by the statistics bureau last month. The growth trajectory puts Taiwan on track to exceed South Korea’s GDP per capita — a key measure of living standards — a
READY TO HELP: Should TSMC require assistance, the government would fully cooperate in helping to speed up the establishment of the Chiayi plant, an official said Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said its investment plans in Taiwan are “unchanged” amid speculation that the chipmaker might have suspended construction work on its second chip packaging plant in Chiayi County and plans to move equipment arranged for the plant to the US. The Chinese-language Economic Daily News reported earlier yesterday that TSMC had halted the construction of the chip packaging plant, which was scheduled to be completed next year and begin mass production in 2028. TSMC did not directly address whether construction of the plant had halted, but said its investment plans in Taiwan remain “unchanged.” The chipmaker started
MORTGAGE WORRIES: About 34% of respondents to a survey said they would approach multiple lenders to pay for a home, while 29.2% said they would ask family for help New housing projects in Taiwan’s six special municipalities, as well as Hsinchu city and county, are projected to total NT$710.65 billion (US$23.61 billion) in the upcoming fall sales season, a record 30 percent decrease from a year earlier, as tighter mortgage rules prompt developers to pull back, property listing platform 591.com (591新建案) said yesterday. The number of projects has also fallen to 312, a more than 20 percent decrease year-on-year, underscoring weakening sentiment and momentum amid lingering policy and financing headwinds. New Taipei City and Taoyuan bucked the downturn in project value, while Taipei, Hsinchu city and county, Taichung, Tainan and Kaohsiung
Micro-Star International Co (MSI, 微星科技) is expanding notebook computer production in India after partnering with Indian electronics maker Syrma SGS Technology Ltd late last year, as the Taiwanese company seeks to tap into the local market. MSI also plans to manufacture some of its new gaming PCs powered by Nvidia Corp’s RTX 50 graphics cards in India, while adding more advanced and design-focused PCs and notebooks at Syrma’s plant in Chennai, a source told the Taipei Times yesterday on condition of anonymity. MSI’s deployment in India is driven not only by cost advantages, but also by India’s rapidly expanding consumer market and
RSS